TD Asset Management Inc Has $14.59 Million Stock Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

TD Asset Management Inc trimmed its position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) by 4.0% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 229,742 shares of the company’s stock after selling 9,520 shares during the period. TD Asset Management Inc’s holdings in Verona Pharma PLC American Depositary Share were worth $14,586,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in VRNA. NBC Securities Inc. acquired a new position in shares of Verona Pharma PLC American Depositary Share in the first quarter worth about $34,000. Vermillion Wealth Management Inc. acquired a new position in shares of Verona Pharma PLC American Depositary Share in the fourth quarter worth about $46,000. GF Fund Management CO. LTD. acquired a new stake in shares of Verona Pharma PLC American Depositary Share during the fourth quarter worth approximately $72,000. Advisors Preferred LLC boosted its holdings in shares of Verona Pharma PLC American Depositary Share by 65.4% during the first quarter. Advisors Preferred LLC now owns 1,599 shares of the company’s stock worth $94,000 after purchasing an additional 632 shares during the period. Finally, Avanza Fonder AB acquired a new stake in shares of Verona Pharma PLC American Depositary Share during the first quarter worth approximately $100,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Verona Pharma PLC American Depositary Share

In other news, insider Kathleen A. Rickard sold 114,984 shares of Verona Pharma PLC American Depositary Share stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $8.82, for a total value of $1,014,158.88. Following the transaction, the insider owned 2,546,472 shares of the company’s stock, valued at $22,459,883.04. This trade represents a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO David Zaccardelli sold 400,000 shares of Verona Pharma PLC American Depositary Share stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $11.40, for a total transaction of $4,560,000.00. Following the completion of the transaction, the chief executive officer directly owned 13,190,168 shares in the company, valued at approximately $150,367,915.20. This represents a 2.94% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,794,984 shares of company stock valued at $18,524,153 over the last three months. 4.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

VRNA has been the subject of several research reports. Piper Sandler cut shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Roth Capital cut shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Canaccord Genuity Group cut shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and set a $107.00 price target for the company. in a report on Wednesday, July 9th. HC Wainwright restated a “neutral” rating and set a $107.00 price target (up from $90.00) on shares of Verona Pharma PLC American Depositary Share in a report on Monday, July 14th. Finally, Wells Fargo & Company cut shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and decreased their price target for the stock from $138.00 to $107.00 in a report on Thursday, July 10th. Eleven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Verona Pharma PLC American Depositary Share currently has a consensus rating of “Hold” and an average price target of $109.00.

Verona Pharma PLC American Depositary Share Price Performance

NASDAQ VRNA opened at $105.14 on Thursday. The company has a quick ratio of 8.73, a current ratio of 8.86 and a debt-to-equity ratio of 1.07. The stock has a market capitalization of $8.95 billion, a PE ratio of -52.57 and a beta of 0.24. The company has a 50 day moving average price of $93.07 and a two-hundred day moving average price of $72.91. Verona Pharma PLC American Depositary Share has a 12-month low of $18.51 and a 12-month high of $105.50.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last posted its earnings results on Tuesday, April 29th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.49. The business had revenue of $98.65 million during the quarter, compared to analyst estimates of $41.47 million. As a group, equities analysts predict that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.